JP2016529320A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529320A5 JP2016529320A5 JP2016540464A JP2016540464A JP2016529320A5 JP 2016529320 A5 JP2016529320 A5 JP 2016529320A5 JP 2016540464 A JP2016540464 A JP 2016540464A JP 2016540464 A JP2016540464 A JP 2016540464A JP 2016529320 A5 JP2016529320 A5 JP 2016529320A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- occurrence
- haloalkylamine
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 8
- 230000007954 hypoxia Effects 0.000 claims 8
- 230000001052 transient effect Effects 0.000 claims 8
- 230000009529 traumatic brain injury Effects 0.000 claims 8
- 208000028867 ischemia Diseases 0.000 claims 7
- 230000016273 neuron death Effects 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 206010003497 Asphyxia Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 claims 2
- 206010050081 Neonatal hypoxia Diseases 0.000 claims 2
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 claims 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims 2
- 206010058571 Spinal cord infarction Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229960003418 phenoxybenzamine Drugs 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874865P | 2013-09-06 | 2013-09-06 | |
| US61/874,865 | 2013-09-06 | ||
| PCT/US2014/054569 WO2015035308A2 (en) | 2013-09-06 | 2014-09-08 | Method of reducing neuronal cell death with haloalkylamines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019011177A Division JP6636660B2 (ja) | 2013-09-06 | 2019-01-25 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529320A JP2016529320A (ja) | 2016-09-23 |
| JP2016529320A5 true JP2016529320A5 (https=) | 2017-10-05 |
| JP6475733B2 JP6475733B2 (ja) | 2019-02-27 |
Family
ID=52629091
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540464A Expired - Fee Related JP6475733B2 (ja) | 2013-09-06 | 2014-09-08 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
| JP2019011177A Expired - Fee Related JP6636660B2 (ja) | 2013-09-06 | 2019-01-25 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
| JP2019227012A Expired - Fee Related JP6865806B2 (ja) | 2013-09-06 | 2019-12-17 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019011177A Expired - Fee Related JP6636660B2 (ja) | 2013-09-06 | 2019-01-25 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
| JP2019227012A Expired - Fee Related JP6865806B2 (ja) | 2013-09-06 | 2019-12-17 | ハロアルキルアミンを用いた神経細胞死の低減方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160220515A1 (https=) |
| EP (1) | EP3041465B1 (https=) |
| JP (3) | JP6475733B2 (https=) |
| CN (2) | CN105530924A (https=) |
| CA (1) | CA2923476C (https=) |
| MX (1) | MX376515B (https=) |
| WO (1) | WO2015035308A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3041465B1 (en) * | 2013-09-06 | 2020-11-11 | The University Of Montana | Method of reducing neuronal cell death with haloalkylamines |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5513661A (en) | 1993-10-14 | 1996-05-07 | Hubbard; David R. | Use of sympathetic blockade for treatment of chronic muscle pain |
| US6009875A (en) | 1993-10-14 | 2000-01-04 | Berlex Laboratories, Inc. | Use of sympathetic antagonists for treatment of chronic muscle pain |
| WO1997007793A1 (en) * | 1995-08-29 | 1997-03-06 | New York Medical College | Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd) |
| EP1235563A2 (en) | 1998-08-26 | 2002-09-04 | Queen's University At Kingston | Use of anti(w)pressor agents for vascular remodeling in genital dysfunction |
| CA2416650C (en) | 2000-07-19 | 2010-09-21 | Pitmy International N.V. | Enhancement of the action of central and peripheral nervous system agents |
| US6730667B2 (en) | 2001-11-26 | 2004-05-04 | William R. Deagle | Iontophoresis disc pain blocker |
| US7172614B2 (en) * | 2002-06-27 | 2007-02-06 | Advanced Cardiovascular Systems, Inc. | Support structures for embolic filtering devices |
| US20040063612A1 (en) * | 2002-09-26 | 2004-04-01 | Manssur Yalpani | Neuroprotective agents |
| US7600349B2 (en) * | 2003-02-26 | 2009-10-13 | Unirac, Inc. | Low profile mounting system |
| US20060128719A1 (en) * | 2004-12-13 | 2006-06-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of alpha-adrenergic blockers for the treatment of dysmenorrhea |
| WO2007057508A2 (en) | 2005-11-18 | 2007-05-24 | Orion Corporation | Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol |
| WO2007062862A2 (en) | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| US20070249725A1 (en) | 2006-02-17 | 2007-10-25 | Hubbard David R | Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain |
| MX2009001966A (es) | 2006-08-23 | 2009-06-19 | Univ Montana | Metodo de reduccion del daño celular neuronal. |
| US20090197969A1 (en) * | 2006-08-23 | 2009-08-06 | Poulsen David J | Method of reducing brain cell damage or death |
| US20110105621A1 (en) * | 2006-08-23 | 2011-05-05 | The University Of Montana | Method of reducing brain cell damage, inflammation or death |
| ES2475193T3 (es) | 2007-01-22 | 2014-07-10 | Gtx, Inc. | Agentes de unión al receptor nuclear |
| US8292830B2 (en) | 2007-05-22 | 2012-10-23 | University Of Louisville Research Foundation, Inc. | Soft tissue impact assessment device and system |
| WO2010148519A1 (en) | 2009-06-25 | 2010-12-29 | Queen's University At Kingston | Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist |
| CN102946896A (zh) * | 2010-04-30 | 2013-02-27 | 西安大略大学 | Sox9抑制剂 |
| WO2012074561A2 (en) | 2010-11-30 | 2012-06-07 | Columbia Northwest Pharmaceuticals Llc | Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders |
| EP2466311A1 (en) | 2010-12-17 | 2012-06-20 | Roche Diagnostics GmbH | sFlt1 in patients with ischemic stroke |
| CA2768796A1 (en) | 2011-02-22 | 2012-08-22 | Wellspring Pharmaceutical Corporation | Phenoxybenzamine assay |
| WO2012162364A1 (en) * | 2011-05-23 | 2012-11-29 | New York Medical College | Phenoxybenzamine for pain |
| US20140371322A1 (en) | 2013-06-13 | 2014-12-18 | Professional Compounding Centers Of America | Phenoxybenzamine Transdermal Composition |
| EP3041465B1 (en) | 2013-09-06 | 2020-11-11 | The University Of Montana | Method of reducing neuronal cell death with haloalkylamines |
-
2014
- 2014-09-08 EP EP14843058.0A patent/EP3041465B1/en not_active Not-in-force
- 2014-09-08 WO PCT/US2014/054569 patent/WO2015035308A2/en not_active Ceased
- 2014-09-08 CA CA2923476A patent/CA2923476C/en not_active Expired - Fee Related
- 2014-09-08 CN CN201480048767.XA patent/CN105530924A/zh active Pending
- 2014-09-08 US US14/916,692 patent/US20160220515A1/en not_active Abandoned
- 2014-09-08 CN CN201910642934.8A patent/CN110251496A/zh active Pending
- 2014-09-08 MX MX2016002655A patent/MX376515B/es active IP Right Grant
- 2014-09-08 JP JP2016540464A patent/JP6475733B2/ja not_active Expired - Fee Related
-
2018
- 2018-10-01 US US16/148,825 patent/US10849865B2/en not_active Expired - Fee Related
-
2019
- 2019-01-25 JP JP2019011177A patent/JP6636660B2/ja not_active Expired - Fee Related
- 2019-12-17 JP JP2019227012A patent/JP6865806B2/ja not_active Expired - Fee Related
-
2020
- 2020-10-28 US US17/082,161 patent/US20210093586A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3251674A3 (en) | Antiviral azasugar-containing nucleosides | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| JP2016517888A5 (https=) | ||
| FI3721882T3 (fi) | Aineenvaihduntahäiriöiden hoito hevoseläimissä | |
| JP2016508134A5 (https=) | ||
| WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| IL294463A (en) | Methods for treating or preventing eye conditions | |
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| JP2015516427A5 (https=) | ||
| JP2011225596A5 (https=) | ||
| JP2020520916A5 (https=) | ||
| AR080736A1 (es) | Composicion farmaceutica de disolucion rapida, usualmente bucodispersable, y proceso para prepararla | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| WO2015070234A3 (en) | Neuroprotective compounds and use thereof | |
| JP2016515550A5 (https=) | ||
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| HRP20171864T1 (hr) | Nove stabilne soli pentadekapeptida, postupak za njihovu proizvodnju, njihova primjena u proizvodnji farmaceutskih pripravaka i njihova uporaba u liječenju | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| JP2014530204A5 (https=) | ||
| JP2016529320A5 (https=) | ||
| JP2016519143A5 (https=) |